References
- Bai F, Freeman BB III, Fraga CH, et al. (2006). Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Anal Technol Biomed Life Sci 831:169–75
- Burris HA III, Taylor CW, Jones SF, et al. (2009). A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15:6702–8
- Chan EC, New LS, Chua TB, et al. (2012). Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos 40:1414–22
- Danish M, Gardner ER, Chen X, Figg WD. (2009). Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Anal Technol Biomed Life Sci 877:355–9
- de Jonge MJ, Hamberg P, Verweij J, et al. (2013). Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 31:751–9
- Geyer CE, Forster J, Lindquist D, et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–43
- Hudachek SF, Gustafson DL. (2013). Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J Pharmacokinet Pharmacodyn 40:157–76
- Hwang K, Acharya MR, Sausville EA, et al. (2004). Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 804:289–94
- Kawada K, Murakami K, Sato T, et al. (2007). Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 37:44–8
- Kummar S, Gutierrez M, Gardner ER, et al. (2007). Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 13:5411–17
- LaBonte MJ, Wilson PM, Fazzone W, et al. (2011). The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 71:3635–48
- Mahmoud R, Abd-elfattah O. (2013). Low dose docetaxel combined with low dose capecitabine in treatment of metastatic breast cancer previously treated with anthracycline. Life Sci J 10:444–9
- Pili R, Salumbides B, Zhao M, et al. (2012). Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106:77–84
- Rezai K, Urien S, Isambert N, et al. (2011). Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol 68:1529–36
- Roche S, McMahon G, Clynes M, O'Connor R. (2009). Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J Chromatogr B Anal Technol Biomed Life Sci 877:3982–90
- Simonelli M, Zucali PA, Lorenzi E, et al. (2013). Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Eur J Cancer 49:989–98